Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025)
Silence Therapeutics (SLN) reported Other Operating Expenses of -$4.0 million for Q2 2025, up 78.62% on a YoY basis from -$2.2 million in Q2 2024, and up 85.95% sequentially from -$28.4 million in Q1 2025.
Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025) Analysis & Trends
Silence Therapeutics (SLN) has 2 years of Other Operating Expenses data on file, last reported at -$4.0 million in Q2 2025.
- For the quarter ending Q2 2025, Other Operating Expenses rose 78.62% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$4.0 million (up 91.52% YoY), and the FY2024 full-year result was -$113.6 million, changed N/A from the prior year.
- Other Operating Expenses grew to -$4.0 million in Q2 2025, from -$28.4 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$4.0 million in Q2 2025 to a low of -$28.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Silence Therapeutics | 1.62 Bn | 1.49 Bn | 411,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -3.99 Mn |
| Mar 31, 2025 | -28.38 Mn |
| Jun 30, 2024 | -18.64 Mn |
| Mar 31, 2024 | -10.77 Mn |